Hodgkin lymphoma in patients with hiv infection: A review

Current Hematologic Malignancy Reports

Volumn 7, Issue 3, 2012, Pages 228-234

  Martis, Nihal ^a   Mounier, Nicolas ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

AIDS; CD4 cell count; EBV; HAART; Hematopoietic growth factors; HIV; Hodgkin's lymphoma; PET scan

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; PREDNISONE; VINBLASTINE; VINCRISTINE; VINORELBINE DITARTRATE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR MICROENVIRONMENT;

ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; EPSTEIN-BARR VIRUS INFECTIONS; FLUORODEOXYGLUCOSE F18; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, AIDS-RELATED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 84865990269     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0125-2     Document Type: Review

References (43)

1. Bohlius J, Schmidlin K, Boué F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood. 2011;117 (23):6100-8. The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.
2. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20(12):1645-54.
3. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21(18):3447-53.
4. Lanoy E, Spano J-P, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer. 2011;129(2):467-75.
5. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884-90.
6. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108 (12):3786-91.
7. Levine AM. Hodgkin lymphoma: to the HAART of the matter. Blood. 2006;108(12):3630.
8. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152-9.
9. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. Eur J Cancer. 2001;37(10):1306-15.
10. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13(7):1758-67.
11. Spina M, Berretta M, Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am. 2003;17(3):843-58.
12. Herndier BG, Sanchez HC, Chang KL, Chen YY, Weiss LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am J Pathol. 1993;142 (4):1073-9.
13. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from postgerminal center B cells. Blood. 1999;93(7):2319-26.
14. Carbone A, Spina M, Gloghini A, Tirelli U. Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol. 2011;86(2):170-9. ABVD remains the gold standard both in nonimmunosuppressed or immunosuppressed hosts.
15. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol. 2007;38(9):1293-304.
16. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339 (21):1506-14.
17. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol. 2004;125(4):455-62.
18. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(4):422-8.
19. Chimienti E, Spina M, Gastaldi R. Clinical characteristics and outcome of 290 patients (pts) with Hodgkin's disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Ann Oncol. 2008;19:136.
20. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood. 2009;113(23):5737-42.
21. Dolcetti R, De Paoli P, Serraino D. Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter. Blood. 2009;114(11):2354. author reply 2354-2355.
22. Gérard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17(1):81-7.
23. Ribera J-M, Navarro J-T, Oriol A, et al. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. AIDS. 2002;16(14):1973-6.
24. Xicoy B, Ribera J-M, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica. 2007;92(2):191-8.
25. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24(5):444-50.
26. Tanaka PY, Pessoa Jr VP, Pracchia LF, et al. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma. 2007;7(5):364-8.
27. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol. 2003;14(10):1562-9.
28. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100(6):1984-8.
29. Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). -ASCO. J Clin Oncol. 2007;25 (18S):8083.
30. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105(2):874-8.
31. Serrano D, Carrión R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;33(4):487-94.
32. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306-13.
33. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14(1):59-66.
34. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet. 2005;44(2):111-45.
35. Mounier N, Katlama C, Costagliola D, Chichmanian R-M, Spano J-P. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol. 2009;72(1):10-20. The concomitant use of antineoplastic chemotherapy and HAART have been demonstrated to be feasible and effective in patients with HIV-related malignancies.
36. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18Ffluoro-deoxyglucose positron emission tomography for posttreatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006;91(4):522-9.
37. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-9.
38. Mounier N, Bower M, Spina M, Besson C. Early determination of treatment sensitivity in HIV-related Hodgkin lymphoma by FDGPET/CT after two cycles of ABVD chemotherapy. Third international workshop on interim-PET in lymphoma. Menton (France). 2011;(abstr A110).
39. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257-60.
40. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25 (5):571-8.
41. Goshen E, Davidson T, Avigdor A, Zwas TS, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med. 2008;33(9):610-4.
42. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 1:S117-127.
43. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50 (4):527-33.